Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Harefuah
|
October 13, 2005
[Prophecy and mental illness]
Tali Vishne, Eran Harary
Value in Health Regional Issues
|
April 29, 2018
Clinical Characterization and the Caregiver Burden of Dementia in China
Boxiong Tang, Eran Harary, Ricky Kurzman, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 22, 2013
The burden of caring for dementia patients: caregiver reports from a cross-sectional hospital-based study in China
Joaquín F Mould-Quevedo, Boxiong Tang, Eran Harary, et al.
Clinical Neuropharmacology
|
November 4, 2008
Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study
Rafael Stryjer, Baruch Spivak, Rael D Strous, et al.
Neuropsychiatric Disease and Treatment
|
May 14, 2026
Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm
Leslie Citrome, Kelli R Franzenburg, Mark Suett, et al.
CNS Drugs
|
July 29, 2025
Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies
Christoph U Correll, Helena Knebel, Eran Harary, et al.
CNS Drugs
|
January 14, 2026
Correction: Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia
John M Kane, Orna Tohami, Kelli R Franzenburg, et al.
CNS Drugs
|
November 21, 2025
Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia
John M Kane, Orna Tohami, Kelli R Franzenburg, et al.
Clinical Pharmacology in Drug Development
|
March 4, 2022
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone
Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, et al.
CNS Drugs
|
June 15, 2026
A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use
Avia Merenlender Wagner, Itay Perlstein, Pavel Farkas, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Harefuah
|
October 13, 2005
[Prophecy and mental illness]
Tali Vishne, Eran Harary
Value in Health Regional Issues
|
April 29, 2018
Clinical Characterization and the Caregiver Burden of Dementia in China
Boxiong Tang, Eran Harary, Ricky Kurzman, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 22, 2013
The burden of caring for dementia patients: caregiver reports from a cross-sectional hospital-based study in China
Joaquín F Mould-Quevedo, Boxiong Tang, Eran Harary, et al.
Clinical Neuropharmacology
|
November 4, 2008
Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study
Rafael Stryjer, Baruch Spivak, Rael D Strous, et al.
Neuropsychiatric Disease and Treatment
|
May 14, 2026
Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm
Leslie Citrome, Kelli R Franzenburg, Mark Suett, et al.
CNS Drugs
|
July 29, 2025
Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies
Christoph U Correll, Helena Knebel, Eran Harary, et al.
CNS Drugs
|
January 14, 2026
Correction: Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia
John M Kane, Orna Tohami, Kelli R Franzenburg, et al.
CNS Drugs
|
November 21, 2025
Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia
John M Kane, Orna Tohami, Kelli R Franzenburg, et al.
Clinical Pharmacology in Drug Development
|
March 4, 2022
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone
Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, et al.
CNS Drugs
|
June 15, 2026
A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use
Avia Merenlender Wagner, Itay Perlstein, Pavel Farkas, et al.
Page
of 2